Evaluation of Ferroptocide (FTC) As a Potential Treatment For Prostate Cancer Cells

https://cancer.uillinois.edu/wp-content/uploads/2020/10/Hillary-Evaluation-of-Ferroptocide-FTC-As-a-Potential-Treatment-For-Prostate-Cancer-Cells.mp4 Hillary Sanatkumar Shah Mentor: Gnanasekar Munirathinam, PhD The American Cancer Society estimates that 191,930 new cases of prostate cancer will be diagnosed this year, with the disease causing 33,330 deaths, making it the second leading cause of cancer death in American men. Existing treatments for prostate cancer include surgery, radiation therapy, chemotherapy, hormonal therapy and immunotherapy. These treatment options show effects in the beginning stages, but ultimately resistance develops in the majority…

Continue Reading

Role of Hyperandrogenism in the Development of Fallopian Tube Derived High Grade Serous Ovarian Cancer

Jose Colina Mentor: Joanna Burdette, PhD An estimated 22,440 women were diagnosed with ovarian cancer last year. Of those individuals, an estimated 14,080 died of the disease, making ovarian cancer the most lethal gynecologic malignancy in the United States. High grade serous ovarian cancer (HGSOC) is the most common subtype of the disease. If caught early, ovarian cancer has a 92.1% five-year survival rate; however, 79% or more of the individuals are diagnosed…

Continue Reading

Cervical Cancer and High-Risk HPV Strains in Chicago: the importance of the “Other”

https://cancer.uillinois.edu/wp-content/uploads/2020/10/Hoda-E-Sayegh-23_audiopres.mp4 Hoda Sayegh Mentor: Gelila Goba, MD Cervical Cancer and High-Risk HPV Strains in Chicago: the importance of the “Other” The National Health and Nutrition Examination Survey indicates that 20.4% of adult women have High-Risk Human Papilloma Virus (hrHPV). Strains 16 and 18 of the virus are most commonly associated with cervical cancer, but HPV strains 31, 33, 35, 39, 45, 51, 52, 56, 58, 66, and 68 have also been identified as…

Continue Reading

Gemcitabine Resistance Requires the Sustained Uptake of Calcium via L-Type Channels and is Reversed by High Dose Amlodipine

https://cancer.uillinois.edu/wp-content/uploads/2020/10/Daniel-Principe-29_audiopres.mp4 Presenter: Daniel Principe Mentor: Ajay Rana, PhD Gemcitabine Resistance Requires the Sustained Uptake of Calcium via L-Type Channels and is Reversed by High Dose Amlodipine Gemcitabine is among the most widely used medications in the treatment of pancreatic cancer. While Gemcitabine-based chemotherapy modestly prolongs survival in both localized and disseminated disease, nearly all tumors either have or will develop some degree of drug resistance. With no approved medications for patients who progress…

Continue Reading

Engaging Multi-Sector Stakeholders to Enhance Support for Young Breast Cancer Survivors: Results of a Virtual Participatory Design Workshop

https://cancer.uillinois.edu/wp-content/uploads/2020/10/Asha-Matthew-26_audiopres.mp4 Presenter: Asha Solomon Mentor: Ardith Doorenbos, PhD, RN Engaging Multi-Sector Stakeholders to Enhance Support for Young Breast Cancer Survivors: Results of a Virtual Participatory Design Workshop Young and A Survivor (YAAS!) is a diverse network of 30 clinical/academic partners, community-based organizations, and young breast cancer survivors dedicated to enhancing support for young women aged 18-45 who are affected by breast cancer. With an emphasis on young survivors in underserved/under-represented communities, YAAS! takes…

Continue Reading

Jag1 as a Novel Extravasation Factor During Triple Negative Breast Cancer Metastasis

https://cancer.uillinois.edu/wp-content/uploads/2020/10/Benjamin-Gordon-20_audiopres.mp4 Presenter: Benjamin Gordon Mentor: Jan Kitajewski, PhD Breast cancer is the second leading cause of cancer-related mortality in women. The primary tumor doesn’t normally cause death, but the spread of the disease does. Up to 20% of breast cancer diagnoses are triple negative breast cancer (TNBC), and the five-year survival rate for the disease in its late stages is as low as 11%. TNBC is unresponsive to hormonal and targeted therapies of…

Continue Reading

Damon Runyon Clinical Investigator Award

The Damon Runyon Cancer Research Foundation is inviting applications for the Damon Runyon Clinical Investigator Award. The award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine.  The awardee will receive $200,000 per year for three years. The Foundation will also retire up to $100,000 of any…

Continue Reading

Rana lab hopes third line medication could be charm for pancreatic cancer patients

Long-term treatment of pancreatic cancer using the chemotherapy drug gemcitabine leads to extensive reprogramming of the immune microenvironment, sensitizing tumors to the benefit of a multi-drug immunotherapy regimen, according to new research from the University of Illinois College of Medicine. Pancreatic ductal adenocarcinoma (PDAC) – the most common form of pancreatic cancer – is projected to be the second leading cause of cancer-related death in the United States, with an overall five-year survival…

Continue Reading

2020 Das Gupta symposium going virtual

The computer screen for the Tapas Das Gupta, MD Virtual Cancer Research Symposium 2020 is filling up, but there’s still room available.The event, to be held Oct. 14 from 9 a.m. to 3 p.m. and hosted by John Stewart IV, MD, MBA, FACS, associate director of clinical research at the University of Illinois Cancer Center, will feature three renowned cancer researchers and clinicians who will discuss a myriad range of healthcare topics. A…

Continue Reading

Kim to co-lead new UIC center for public health data analytics

University of Illinois Cancer Center member Sage Kim, PhD, was selected to co-lead the University of Illinois Chicago School of Public Health’s new Population Health Analytics, Metrics and Evaluation, or PHAME, center.The PHAME Center at UIC will combine novel technology with academic expertise to provide a hub of advanced data visualization, evaluation, and analytics to community members, students, policymakers and researchers in Chicago and beyond. By combining these elements – community, scholars and…

Continue Reading